• Mortada H F El-Shabrawi, Naglaa M Kamal, Engy A Mogahed, Mona A Elhusseini, and Mohamed F Aljabri.
• Department of Pediatrics and Pediatric Hepatology, Faculty of Medicine, Cairo University, Egypt.
• Arch Med Sci. 2020 Jan 1; 16 (6): 1360-1369.

AbstractInfection with hepatitis C virus (HCV) is a major health problem worldwide. A large proportion of perinatal HCV infections are silent and may present later in adulthood with long-term complications. HCV has no effective immune prophylaxis and hence appropriate follow-up of all infants born to HCV-infected mothers is necessary. Universal antenatal screening for HCV is largely debatable. Intrauterine and partum transmission of HCV are both possible and higher rates are associated with a high maternal serum viral load (> 106 copies per milliliter), concomitant HIV infection, prolonged or difficult delivery, and invasive fetal monitoring during delivery. Infection during pregnancy and infancy needs to be investigated more in order to design management strategies for perinatal transmission of HCV most effectively. The recently approved new-generation, oral, direct-acting antiviral drugs may open a new era in HCV therapy for pregnant women and infected infants if proved to be safe during conception and infancy.Copyright: © 2019 Termedia & Banach.

5 keywords...

hide…